The past year has been a wild ride for shareholders of clinical-stage biotech Olema Pharmaceuticals (OLMA). Despite a sharp pullback in recent months, the stock is still up an eye-popping 276% over the past 12 months, dramatically outperforming the S&P 500’s roughly 19% gain.
But as the company approaches a crucial readout of Phase 3 data for its lead breast cancer candidate, two starkly contrasting moves by major players are giving investors plenty to ponder. On one side, top-tier healthcare investment firm Cormorant Asset Management built a new $68.8 million stake in the fourth quarter. On the other, board member Ian Clark completely cashed out his position in December, selling nearly $7.9 million worth of stock near the all-time high.
According to a Feb. 17 SEC filing, Cormorant Asset Management established a new position in Olema during the fourth quarter, purchasing 2.75 million shares valued at $68.75 million as of Dec. 31. Based on quarter-end pricing, the fund’s average entry cost sits around $25 per share. The position represents 3.18% of Cormorant’s reported 13F assets under management — a meaningful allocation that signals conviction despite not cracking the firm’s top five holdings.
The timing is telling. Olema’s explosive rally began in late November, following a string of analyst upgrades, encouraging clinical updates for its lead candidate palazestrant (OP-1250), and a $218 million equity offering that transformed the company’s balance sheet. The market broadly views Cormorant’s entry as a bet on palazestrant’s upcoming catalysts.
Yet even as Cormorant was accumulating shares, one insider made a decisive exit. A Dec. 19 Form 4 filing shows Clark exercised options and immediately sold 264,800 shares at a weighted average price of $29.73, for total proceeds of approximately $7.87 million. More striking than the size is the finality: after the transaction, Clark’s direct and indirect ownership both stood at zero.
Clark’s execution was impeccable. His sale price represented a 7.5% premium to that day’s closing price of $27.93 and came just as the stock peaked. Since then, shares have retreated more than 40% to around $16.60, meaning Clark avoided over $3 million in potential losses by locking in gains near the top.
The divergent moves reflect fundamentally different assessments of Olema’s risk-reward profile heading into a binary catalyst.
For Cormorant and investors like it, the appeal lies in palazestrant’s commercial potential. The drug, a novel oral SERD (selective estrogen receptor degraver) targeting ER-positive, HER2-negative breast cancer, is currently being evaluated in two pivotal Phase 3 trials. Top-line data from the OPERA-01 monotherapy study is expected in the fall of 2026. Positive results could transform Olema from a clinical-stage story into a commercial oncology player targeting a multi-billion dollar market opportunity. With approximately $505 million in cash, equivalents and marketable securities as of year-end 2025 (including the November raise), the company is funded into 2028, giving it ample runway to reach and navigate potential commercialization.
For Clark, who has been with the company through its evolution from early research to late-stage development, the calculus was different. His sale stemmed from option exercises — essentially converting years of paper gains into actual cash. After watching the stock appreciate more than 300% in a year, taking money off the table is a rational wealth preservation move. The biotech sector is notoriously binary: even positive Phase 3 data doesn’t guarantee commercial success, and a negative readout can wipe out 80% or more of a company’s value overnight.
The Cormorant-Clark divergence offers a masterclass in biotech investing psychology. The hedge fund’s purchase represents a classic left-side bet — positioning before a major catalyst in hopes of a multi-bagger return, while accepting the risk of total loss. Clark’s sale is textbook right-side harvesting — locking in gains after a massive run-up and declining to gamble on what comes next.
With the stock now down about 45% from its December peak, much of the euphoria has faded. But that also means the bar for upside has lowered: a positive data readout this fall could easily send shares rocketing again. For individual investors, the key question is one of temperament and risk tolerance. Are you willing to bet alongside Cormorant that palazestrant will deliver, accepting the binary risk that comes with it? Or do you follow Clark’s lead, recognizing that after a 300% run, preserving capital is a perfectly valid strategy?
The bottom line: Olema’s story is far from over. Cormorant’s entry adds institutional credibility, but Clark’s exit serves as a sobering reminder of biotech’s unforgiving math. When palazestrant’s Phase 3 data hits later this year, we’ll finally learn which side made the right call. Until then, the contrasting moves offer plenty of food for thought.
